I spoke with Caribou $CRBU CEO Rachel Haurwitz last night about the gut-wrenching decision to shut down after failing to raise money to move its off-the-shelf CAR-T for lymphoma into a Phase 3 study.

“Biotech companies close all the time, usually because the idea didn’t work, or the drug didn’t work. So, you wind down. You learned something, and you move on,” Haurwitz said.

“Our experience is incredibly disappointing. Our clinical signal is strong. The benefit to patients is compelling and commercial research shows the drug could be market-leading. But all of that isn’t enough in this fundraising environment to get over the hurdle to raise enough capital,” she added.

https://www.statnews.com/2026/10/07/caribou-biosciences-shutting-down-lymphoma-car-t-therapy/